No PFS Benefit With Carotuximab in Advanced Angiosarcoma
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Sarcoma
Fyarro Now Available for Malignant Perivascular Epithelioid Cell Tumor
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Sarcoma Symptom Management, QOL, Communication Improved With Journaling
Crossover randomized study sought to determine if structured journaling could lead to improved quality of life, symptom management, and communication with the clinical care team.
Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma
Young adults were more likely to receive chemotherapy.
Triplet Deemed New Standard Care for Relapsed or Refractory Rhabdomyosarcoma
Adding temozolomide to vincristine and irinotecan improved survival.
CMB305 Vaccine Demonstrates Activity But Doesn’t Improve Survival in Soft-Tissue Sarcomas
CMB305 increased antibody responses and NY-ESO-1-specific T-cell responses.
Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
Expanding HDR Brachytherapy Program at a Rural Cancer Center to Include Soft Tissue Sarcoma
A facility in northwest Montana shares its experiences with developing a brachytherapy service and expanding it to include treatment of soft tissue sarcoma.
Radiomic, Clinical Features Predicted Sarcoma Response to Radiation
Radioresistant sarcoma may require treatment intensification.
Radiation for Abdominal, Pelvic Cancers Ups Secondary Sarcoma Risk
Compared with patients who undergo surgery alone for abdominal or pelvic cancers, those who receive radiation and chemotherapy are at elevated risk for secondary sarcomas.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Sarcoma
Loading... 
Loading...